<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008146</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY20060171 (Aim 1)</org_study_id>
    <secondary_id>R01DA026472</secondary_id>
    <secondary_id>STUDY19110156</secondary_id>
    <nct_id>NCT05008146</nct_id>
  </id_info>
  <brief_title>Imaging CRF X NOP Interactions in CUD</brief_title>
  <official_title>Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajesh Narendran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses [11C]NOP-1A positron emission tomography (PET) and a hydrocortisone challenge&#xD;
      to image the interaction between nociceptive opioid peptide (NOP) receptors and&#xD;
      cortisol/corticotrophin releasing factor (CRF) in subjects with cocaine use disorders (CUD)&#xD;
      and matched healthy controls (HC). It will also examine whether alterations in CRF x NOP&#xD;
      interactions predict relapse in subjects with CUD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine use disorder (CUD) is a chronic disorder associated with numerous relapses and&#xD;
      periods of abstinence.&#xD;
&#xD;
      Studies in CUD suggest that ~ 60 to 75% of abstinent addicts relapse over twelve months&#xD;
      Documenting specific neurochemical abnormalities that lead to relapse in individuals with CUD&#xD;
      has the potential to accelerate the development of medications to prevent relapse. Basic&#xD;
      investigations postulate an imbalance between brain stress and anti-stress/resilience systems&#xD;
      as the underlying mechanism that drives negative reinforcement, craving, and relapse in&#xD;
      addiction. Nociceptin (N/OFQ), which binds to the nociceptive opioid peptide receptors (NOP)&#xD;
      is a critical component of the brain's anti-stress system. N/OFQ counteracts the functional&#xD;
      effects of the primary stress-promoting neuropeptide corticotrophin releasing factor (CRF) in&#xD;
      the brain to exert its anti-stress effects. Studies have also shown that acute increases in&#xD;
      CRF and stress are countered by increased NOP receptor expression (~ 10% ) in brain regions&#xD;
      that regulate stress such as bed nucleus of the stria terminalis. PET studies with the NOP&#xD;
      radiotracer [11C]NOP-1A show increased binding to NOP in CUD compared to HC. PET studies also&#xD;
      show NOP receptors to upregulate (~ 15%) in response to an acute intravenous hydrocortisone&#xD;
      challenge (1 mg/Kg). NOP upregulation may represent an adaptive mechanism in the brain to&#xD;
      counteract stress-induced increases in cortisol and CRF. Here, we postulate a failure in this&#xD;
      adaptive mechanism as a reason that leads to relapse in CUD. CUD subjects and HC will be&#xD;
      studied with [11C]NOP-1A before and after an intravenous hydrocortisone challenge (aim 1).&#xD;
      Hydrocortisone is used as a challenge because it increases cortisol and CRF in brain regions&#xD;
      that regulate stress. We hypothesize that hydrocortisone-induced increases in [11C]NOP-1A&#xD;
      binding (DELTA VT) will be smaller in CUD relative to HC, and this will be associated with&#xD;
      less time to relapse in a 12-week follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2028</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cocaine Use disorder and Healthy control groups will receive same interventions</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DELTA VT</measure>
    <time_frame>Baseline, and 3 hours post-hydrocortisone</time_frame>
    <description>VT is the volumes of distribution expressed relative to total plasma ligand concentration; Delta VT is the change in VT from baseline to 3-hours post-hydrocortisone.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cocaine Use Disorder</condition>
  <arm_group>
    <arm_group_label>PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[C-11]NOP-1A</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Baseline [C-11]NOP-1A PET Scan</intervention_name>
    <description>Radiotracer</description>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Intravenous, 1mg/Kg</description>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Post-hydrocortisone [C-11]NOP-1A PET Scan</intervention_name>
    <description>Radiotracer</description>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Cocaine use disorders (CUD)&#xD;
&#xD;
          1. Males or females between 18 and 55 years old&#xD;
&#xD;
          2. Fulfil DSM-5 criteria for cocaine use disorder&#xD;
&#xD;
          3. No other current DSM-5 psychiatric or addictive disorders (such as major depressive&#xD;
             disorder, bipolar disorders, psychotic disorders, etc.,)&#xD;
&#xD;
          4. No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, MDMA,&#xD;
             etc., as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine&#xD;
             use will be quantified and controlled between groups using the Fagerstrom Test for&#xD;
             Nicotine Dependence (Heatherton et al., 1991);&#xD;
&#xD;
          5. Not currently on prescription medical or psychotropic medications&#xD;
&#xD;
          6. No current or past severe medical, endocrine or neurological illnesses including&#xD;
             glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a&#xD;
             complete medical history and physical&#xD;
&#xD;
          7. Not currently pregnant or breastfeeding&#xD;
&#xD;
          8. No history of significant radioactivity exposure in past year from another research&#xD;
             study or occupation that exceeds RDRC guidelines&#xD;
&#xD;
          9. No metallic objects in the body that are contraindicated for MRI&#xD;
&#xD;
        Healthy Controls (HC)&#xD;
&#xD;
          1. Males or females between 18 and 55 years old&#xD;
&#xD;
          2. No present or past DSM-5 disorders (other than nicotine dependence)&#xD;
&#xD;
          3. Criteria 5 to 9 as listed previously.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Narendran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajesh Narendran, MD</last_name>
    <phone>4126475176</phone>
    <email>narendranr@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Narendran</last_name>
      <phone>412-647-5176</phone>
      <email>narendranr@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Rajesh Narendran</investigator_full_name>
    <investigator_title>Professor of Radiology and Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Cocaine use disorder</keyword>
  <keyword>[C-11]NOP-1A PET</keyword>
  <keyword>Nociceptive opioid peptide receptors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

